Metformin causes modest but consistent weight loss in most people who take it — strongest in people with insulin resistance, prediabetes, or metabolic syndrome. Average weight loss in clinical studies:
- Diabetes Prevention Program (DPP — best evidence): 2.1 kg (4.6 lbs) average over 3 years in adults with prediabetes on metformin 850mg twice daily; 29% achieved ≥5% weight reduction
- Meta-analyses: ~1.5–3.5 kg (3–8 lbs) mean loss over 6–12 months in non-diabetic adults — consistently better than placebo, far less than GLP-1s (10–22%)
How Metformin Produces Weight Loss
- GLP-1 stimulation: Metformin increases GLP-1 secretion from intestinal L-cells — the same hormone GLP-1 agonists pharmacologically mimic. Smaller effect than exogenous injection, but contributes to reduced appetite and earlier satiety.
- AMPK activation: Shifts cells toward fat oxidation and away from energy storage; increases fatty acid oxidation in skeletal muscle
- Reduced hepatic glucose output: Lowers circulating insulin in people with hyperinsulinemia — lower insulin means reduced lipogenesis and less hormonal drive toward fat accumulation
- Gut microbiome changes: Emerging evidence that metformin significantly alters gut microbiome composition in ways that contribute independently to weight and metabolic benefit
Who Benefits Most
- Insulin resistance or prediabetes (fasting glucose 100–125 or A1C 5.7–6.4%) — highest hyperinsulinemia-driven fat accumulation; greatest response to insulin sensitization
- PCOS — metformin is frequently used for PCOS-associated weight gain and insulin resistance
- Antipsychotic-induced metabolic weight gain (olanzapine, quetiapine, clozapine, lithium) — metformin is the evidence-supported intervention for this specific iatrogenic cause
- GLP-1 add-on — addresses insulin resistance through a different pathway than GLP-1 agonists; useful for metabolic syndrome and plateau management
Metformin as Add-On to GLP-1 Therapy
At YourMD, metformin ER is available as a $15/month add-on to GLP-1 programs. For patients with prediabetes starting GLP-1 therapy, the combination targets the problem from two mechanistic angles (appetite + insulin sensitization) and adds the DPP-proven diabetes prevention benefit. AMPK activation from metformin also provides mechanistic overlap with longevity effects — relevant for patients interested in both weight management and longevity.
Side Effects
- GI effects (most common): Nausea, diarrhea, bloating — significantly reduced by ER formulation taken with food. Start at 500mg and titrate over 2–4 weeks.
- B12 deficiency: Long-term use reduces B12 absorption. Annual B12 monitoring recommended for anyone on metformin >1 year.
- No hypoglycemia: Does not cause low blood sugar as monotherapy in non-diabetic patients
- Lactic acidosis (rare): Meaningful risk only in severe kidney impairment (eGFR <30). Contraindicated at eGFR <30. Kidney function reviewed before prescribing.
Metformin is not a GLP-1 substitute for primary weight loss. For 10%+ weight reduction, semaglutide or tirzepatide will produce far greater results. Metformin's 2–5% average weight loss is meaningful as an add-on or for specific populations. Your physician will help determine what combination makes sense for your profile.
Related: GLP-1 Weight Loss Drugs 2026: Complete Comparison · Metformin for Longevity: AMPK, mTOR, and the TAME Trial